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Penetrance and age of onset of ATTRV30M amyloidotic neuropathy varies signiﬁcantly among different
populations. This variability has been attributed to both genetic and environmental modiﬁers. We stu-
died the effect of genetic background on phenotype in two lines of transgenic mice bearing the same
ATTRV30M transgene. Amyloid deposition, transthyretin (TTR), megalin, clusterin and disease markers of
endoplasmic reticulum stress, the ubiquitin-proteasome system, apoptosis, and complement activation
were assessed with WB and immunohistochemistry in donor and recipient tissue. Our results indicate
that genetic background modulates amyloid deposition by inﬂuencing TTR handling in recipient tissue
and may partly account for the marked variability in penetrance observed in various world populations.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Familial amyloidotic neuropathy (FAP) Type I is an autosomal
dominant sensorimotor neuropathy due to amyloid deposition in
which the main polypeptide component is transthyretin (TTR).
Mutation of valine to methionine at position 30 is the commonest
variant hence it is named ATTRV30M neuropathy. Penetrance and
age of onset of ATTRV30M neuropathy varies signiﬁcantly among
different populations. Penetrance in Sweden, Cyprus and Portugal
is 2%, 28% and 80% while the age of onset is 52, 46 and 32 years
respectively [1]. This country-speciﬁc variability in penetrance is
unusual for an autosomal dominant disease caused by an identical
mutation and has been attributed to genetic and environmental
modiﬁers [2–4].
We investigated the effect of genetic background on TTR
amyloidosis using two different genetic backgrounds of a trans-
genic mouse model of ATTRV30M amyloid neuropathy. The mice
were null for the endogenous TTR and homozygous for the human
ATTRV30M mutation, one on a 129 1/SvJ background and the
other on a mixed 1291/SvJ/C57BL/6J background. Both genetic
backgrounds had the same human transgene copy number and a
similar number of RNA transcripts in liver tissue, the main site of
TTR synthesis. We carried out a semi-quantitative comparison ofB.V. This is an open access article u
and Genetics, 6, International
).TTR amyloid deposition and of megalin and clusterin expression,
both of which are increasingly recognized for their role in tissue
handling of amyloidogenic peptides [5–9]. In addition, a number of
molecular markers involved in ATTRV30M disease pathogenesis
were assessed including BiP (endoplasmic reticulum stress), ubi-
quitin (ubiquitin-proteasome system), Fas and Caspase 3 (apop-
tosis) and C5b9 (complement activation). We demonstrate that
cross-bred 1291/SvJ/C57BL/6J mice exhibit signiﬁcantly less
amyloid deposition and secondary disease markers which are as-
sociated with signiﬁcantly higher megalin and clusterin up-reg-
ulation. Thus genetic background does appear to modulate amy-
loidogenesis in the ATTRV30M neuropathy model and a number of
players involved in misfolded protein handling may be involved.2. Materials and methods
2.1. Animal and tissue handling
All animals were originally derived from the same transgenic
mouse line [10,11]. They are both null for murine TTR and
homozygous for the ATTRV30M transgene but on two different
genetic backgrounds; the 1291/SvJ background (as of now shall
be referred to as: TM 129) and the 129 1/SvJ/C57BL/6J hybrid
outcross background (as of now shall be referred to as: TM 129/
BL6). Two 129 1/SvJ and two C57BL/6J animals of the appropriate
age group, depending on the application, were used as wild typender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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The mTTR /hTTRV30M/V30M mice were generated from a single
pair of mTTR / hTTRV30M mice (of 129 1/SvJ background, ob-
tained from M. J. Saraiva) that were crossed amongst them to
generate mTTR/hTTRV30M/V30M pups. These were then inter-
crossed to generate the colony of experimental mice. The number
of copies of the V30M transgene was monitored by real time PCR.
These mice are referred to as TM 129.
To generate the TM 129/BL6 colony, male mice
mTTR /hTTRV30M/V30M (in 1291/SvJ background) were crossed
to C57BL/6J females in order to generate F1 mice mTTRþ /
hTTRV30M. These were then inter-crossed to generate F2
mTTR /hTTRV30M/V30M mice which were then bred to generation
7 through successive brother-sister mating. These F7 progeny were
used to produce the experimental mouse line which was used
throughout the experiments. Speciﬁcally, the F7 generation we
used was made up of 2 males and 6 females. Their progeny is
considered to be of mixed genetic background, segregating alleles
of 129 1/SvJ and C57BL/6J origin.
Real time PCR was used to ensure that all animals included in
the experiment had the same copy of transgenes (Fig. 1A). Fur-
thermore reverse transcription real time PCR was used to conﬁrm
that RNA expression for human TTR was similar in liver tissue of
the two backgrounds used in the experiments (Fig. 1B).
Three groups of animals were used from each background;
group A (3–6 months), group B (9–12 months) and group C (15–18
months). Each TM 129 age group was comprised of 15 mice (7 M/
8 F), whereas each TM 129/BL6 group was comprised of 10 mice
(5 M/5 F) each. All animals were kept in a regular 12 h light-12h
dark cycle and were given free access to water and food, under SPF
conditions. Animals were separated in cages depending on the age
group they were assigned to and their sex. All animal involving
experiments were carried out in accordance to the 86/609/EEC
Directive.
Mice were anesthetised and then euthanized using Tri-
bromoethanol (Avertin) though IP injection at a dose of 250 mg/
Kg. The animals were then exsanguinated via PBS perfusion to
reduce the contribution of plasma in the measurements. Tissues
were obtained at the required time points. Tissues were processed
for immunohistochemistry by carrying out overnight 4% PFA
ﬁxation followed by wax embedding or were frozen and kept at
80 °C for western blot analysis.
Amyloid deposition assessment was conﬁned to stomach tis-
sues since this organ is heavily involved in amyloid deposition at
an early age in this model of ATTRV30M neuropathy.Fig. 1. (A) Real-time PCR results of the number of transgene copies found in the ani
transcription real-time PCR results from the liver tissue of TM129 pure background and
expressed in liver, (C)Western blot of TM129 stomach samples from different mice and a
of monomers.2.2. Genotyping
Animals were routinely genotyped using the PCR method. Pri-
mers for the mouse TTR gene (mTTR F 5′ - CTG ACC CAT TTC ACT
GAC ATT T - 3′&mTTR R 5′ - CAA ATG GGA ACC TGG AAC C - 3′) and
the human mutated transgene (hATTRV30M F 5′ – TGCTGATGA-
CACCTGGGAGC – 3′ & hATTRV30M R 5′ TCAGGTTCCTGGTCACTTCC
- 3′) were utilized for screening with annealing temperature at
58 °C.
2.3. Transgene zygosity assessment
For transgene zygosity assessment, the qPCR LightCycler Fas-
tStart DNA Master SYBR Green I assay (Roche Cat. No. 12 239 264
001) was used according to the manufacturer's instructions. The
primers (same used for hATTRV30M genotyping) were used at
0.5 μM concentration each. Wild type mice (without the trans-
gene), heterozygote and homozygous mice were used as controls
to allow for result interpertation. The GAPDH gene was used as a
run control for normalization (mGAPDH F 5′ – CGACTTCAA-
CAGCAACTCCCACTCTTCC – 3′ & mGAPDH R 5′ TGGGTGG-
TCCAGGGTTTCTTACTCCTT - 3′) [12] (Fig. 1A).
2.4. hTTR mRNA Expression in liver tissues
Two-step RT-qPCR was carried out to quantify the expression of
hTTR in the liver. Liver tissue was extracted following animal ex-
sanguination via PBS perfusion. Approximately 25 mg of liver tissue
was removed and lysed using the RNeasy Mini QIAcube Kit (74116).
RNA concentration was assessed by Nanodrop2000 and maximum
100 ng/ml was used for cDNA synthesis. The Invitrogen SuperScript™
II Reverse Transcriptase (18064-022) was used to synthesize ﬁrst-
strand cDNA according to the manufacturer's instructions.
TaqMans Gene Expression Assay for human TTR was then
used, containing a pair of unlabelled PCR primers and a TaqMans
probe with a FAM™ dye label on the 5′ end, and minor groove
binder (MGB) non-ﬂuorescent quencher (NFQ) on the 3′ end. 5 ml
2x TaqMans Gene expression master mix was used with 0.5 ml
hTTR primer probe mix (Hs00174914_m1, 4331182) and 2 ml cDNA
in a total reaction of 10 ml. The GAPDH (4352932E) gene was used
as an endogenous control in delta Ct normalization of samples. For
each liver sample duplicate reactions were run (Fig. 1B).
2.5. Western blots and densitometry
The amount of each protein under investigation was expressed
as a ratio of the intensity of the protein band divided by themals of TM129 pure background and TM129/BL6 mixed background, (B) Reverse
TM129/BL6 mixed background animals measuring the amount of human TTR RNA
single wild type 129 animal for hTTR and GAPDH. The strong TTR band seen consists
Fig. 2. (A) Amyloid plaque in the stomach that stains with Congo red and exhibits apple green birefringence (Ai&Aii). The same plaque stains Thioﬂavin S positive (Aiii) and
is composed of human transthyretin (Aiv). The area of co-localization of Thioﬂavin S and TTR labelling appears yellow (Av) and morphometric measurements are carried out
with the Image J software (Avi), (B) Morphometric comparison of amyloid deposition in the two backgrounds. Western blots of human non ﬁbrillar TTR in the transgenic
animals of the two backgrounds: in the liver (C), the serum (D) and stomach tissue (E).
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mouse SC-32233 1/4,000 and Jackson ImmunoResearch anti-
mouse 115-035-003, 1/5,000) to account for variations due to
loading, even though the amount of protein loaded was previously
quantiﬁed using the standard Bradford assay. This ratio was nor-
malized by dividing it by the ratio obtained, in the same Western
blot, from a standard control mouse. The same standard mouse
was used to normalize all Western blots across different back-
grounds and age groups. Each sample was run in triplicate and the
average normalized ratio was used for comparison. Image J was
used to carry out densitometry calculations.
2.6. TTR Western blot
The animals were exsanguinated after sacriﬁce so that blood TTR
could be eliminated as much as possible. Stomach homogenate was
separated via reducing SDS-PAGE and transferred onto nitrocellulose
membranes. The membranes were blocked with 5% low fat dry milk
(Régilait) for one hour at room temperature. The membranes were
then incubated overnight at 4 °C with anti-human Transthyretin
(TTR) (DAKO A000202) at a dilution of 1/2,000. The antibody was
visualized using the Amersham ECL Western Blotting Detection Re-
agent (RPN2232) after incubating with anti-rabbit secondary anti-
body at 1/5,000 (Jackson ImmunoResearch 111-035-003) for one
hour at room temperature. It should be noted that for TTR, due to the
denaturing conditions, only monomers (14 kDa) were measured
(Fig. 1C) so that only non-ﬁbrillar hTTR can be visualized since pla-
que-bound hTTR needs to be otherwise extracted [13].
Stomach TTR was measured in all animals. Serum and liver TTR
was similarly measured by western blot in 3–5 animals from each
of the two transgenic backgrounds using a control for
normalization.
Blood samples were collected without sacriﬁcing any of the
animals, from the orbital sinus in the absence of anticoagulant. The
samples were allowed to stand overnight at 4 °C to coagulate. They
were then centrifuged at 3500 rpm for 10 min and the top layerwas collected in order to obtain the serum. Samples were diluted
1/10 using injection water prior to western blot analysis as
aforementioned. However the samples mixed with loading buffer
were not boiled but were instead heated at 65 °C for 15 min to
avoid protein coagulation.
2.7. Other Western blots
The same method was applied as with TTR for the following
antibodies; Clusterin (Santa Cruz Biotechnology anti-rabbit sc-
8354 1/500) GRP78 (BiP) (Santa Cruz Biotechnology anti-rabbit sc-
13968 1/1000) and ubiquitin (Santa Cruz Biotechnology anti-rabbit
sc-9133 1/1500).
2.8. Amyloid plaque visualisation and quantiﬁcation
Thioﬂavin S stain combined with TTR immunoﬂuorescence
were used to identify amyloid deposits in parafﬁn sections ob-
tained from stomach tissues. Parafﬁn sections were deparafﬁnised
and hydrated to distilled water. Sections were then stained with
Mayer’s haematoxylin for 5 min, washed further with distilled
water and then stained with aqueous 1% Thioﬂavin S solution
(T1892-25G) for a further 5 min and ﬁnally differentiated in 50%
ethanol before been rinsed with distilled water and then mounted
using the DAKO Fluorescence Mounting Medium (S3023). Thio-
ﬂavin S positive deposits were further conﬁrmed to be amyloid by
electron microscopy (data not shown). In the cases where double
staining with Thioﬂavin S and hTTR antibody were performed,
antibody immunohistochemistry was carried out ﬁrst followed by
staining with Thioﬂavin S standard protocol but omitting the
Mayer’s haematoxylin ﬁnal staining [14]. Plaques positive for both
Thioﬂavin S and hTTR were measured using the Image J software
set to measure yellow (570–585 nm) (Fig. 2A). TTR amyloid pla-
ques were measured over the entire area of stomach section, a
percentage of the surface area occupied by plaques was calculated
and an average percentage obtained over three serial sections.
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Parafﬁn sections from animals’ stomachs were deparafﬁnised
and hydrated to distilled water. Sections were then blocked with
5% BSA solution in PBS for 1 hour at room temperature and then
incubated with the appropriate primary antibody overnight at 4 °
C. The primary antibody used was the anti-human Transthyretin
(TTR) from DAKO (A000202) at a dilution of 1/500. The slides were
then incubated with Invitrogen Alexa Fluor 555 ﬂuorescence
secondary antibody for 1hour at room temperature at 1/2,000
(anti-rabbit A-21428). Finally sections were washed with PBS
and mounted using the DAKO Fluorescence Mounting Medium
(S3023).
Further analysis was carried out using supplementary anti-
bodies; Fas (Santa Cruz Biotechnology anti-rabbit sc-10231/1000)
and activated Caspase-3 (Santa Cruz Biotechnology anti-goat sc-
1225 1/500) to assess apoptosis, GRP78 (Santa Cruz Biotechnology
anti-rabbit sc-13968 1/1000) to assess the endoplasmic reticulum
stress response, and C5b-9 (EMD Millipore anti-rabbit 204903 1/
4,000) to assess complement activation and Megalin (Santa Cruz
Biotechnology anti-goat sc-16478 1/400). The appropriate sec-
ondary antibodies were used, anti-rabbit (Alexa Fluor A-21428 1/
2000) and anti-goat (Alexa Fluor A-21432 1/2000). ECL was used
to visualize the antibodies as previously explained.
2.10. Morphometric image analysis
This analysis was carried out to measure areas of positivity by
immunoﬂuorescence among the various animals. Pictures were
taken using a Zeiss ﬂuorescence microscope using the 20 ob-
jective lens (for measurement purposes). Four (4) pictures were
taken of each stomach in order to visualize the entire stomach
cross section. Percentage area of antibody positivity was measured
using the Image J software set to measure red (665–700 nm) and
averaged from three serial cross sections for each animal. A control
(wild animal) was similarly measured to obtain an indication of
background positivity.
2.11. Statistical analyses
Using the Microsoft Ofﬁce Excel 2010 suite, mean, standard
deviation and p-values were calculated. Using this information,
graphical charts representing the data were prepared. The error
bars depicted represent the standard deviation (1 SD) for each
group of data.3. Results
The main hallmark of FAP Type I neuropathy is the extracellular
deposition of amyloid ﬁbrils composed of TTR protein. Detectable
amyloid deposits (by Thioﬂavin S/TTR immunoﬂuorescence) in the
stomach appear after the age of six months. Our results indicate
that TTR amyloid deposition was not statistically different between
the two genetic backgrounds between ages 9–12 months but by
the age of 15–18 months amyloid deposition was signiﬁcantly
higher in the TM129 mice by about 30% compared to the TM129/
BL6 (Fig. 2B).
We next asked if this difference was due to differences in the
production of TTR in the liver, the major organ of TTR production
and subsequent release in the serum. Western Blot analysis in-
dicated no signiﬁcant difference in liver TTR among the two
transgenic backgrounds (Fig. 2C). However, TTR measured in the
serum was signiﬁcantly lower in the TM 129/BL6 compared to the
TM 129 background (Fig. 2D) at all ages. As the animals aged there
was reduction in circulating TTR in both backgrounds, whichcoincided with appearance of amyloid deposits. Serial body
weights did not differ signiﬁcantly between the two backgrounds
for any of the age groups (data not shown). Non-ﬁbrillar TTR, was
also signiﬁcantly lower in the TM 129/BL6 as compared to the
TM129 background between the ages of 3–6 months (Fig. 2E).
There was also a great reduction in the tissue levels of non-ﬁbrillar
TTR in Group B of both lines, which coincided with the appearance
of amyloid deposits. Signiﬁcant difference was also observed
during the third group.
Previous studies demonstrated that BiP, a major regulator of
endoplasmic reticulum (ER) function involved in both protein
folding and assembly, has been found to be over-expressed in
tissues of FAP patients and transgenic mice. We evaluated the
expression of this marker in donor tissue (liver), as a means of
evaluating the stress imposed on the ER by misfolded intracellular
TTR, and recipient tissue (stomach) as a means of evaluation ex-
tracellular stress due to extracellular TTR. In the liver, BiP levels
were not statistically different between the two genetic back-
grounds but was overexpressed compared to wild type animals
(Fig. 3A). In the stomach, BiP appeared to be overexpressed in both
backgrounds compared to wild type animals, before the appear-
ance of amyloid deposits, but less so in the TM 129/BL6 mice
(Fig. 3C).
We then analysed ubiquitin which is expressed in all cells and
is central in the degradation of aberrant/misfolded proteins. In TTR
amyloidosis ubiquitin has been shown to be up-regulated by ex-
tracellular amyloid. We found that its level was signiﬁcantly higher
in the TM129/BL6 background in both stomach (despite the lower
amyloid deposits) and in liver. In both backgrounds there was up-
regulation of ubiquitin compared to control in the liver tissue
(Fig. 3B), whereas in the stomach a signiﬁcant difference was re-
corded between the transgenic backgrounds wild type animals in
the third age group (Fig. 3D).
Increased amyloid deposition leads to complement activation
and increased apoptotic events in TTR amyloidosis. We thus tested
markers for apoptosis (Fas and Caspase-3) and complement acti-
vation (C5b-9) and found them all up-regulated in both transgenic
backgrounds in an age dependent manner with the TM129 mice
exhibiting higher expression than the TM 129/BL6 background
(Fig. 4). The up-regulation predated the appearance of amyloid
deposits.
Finally, Megalin, a protein that acts as a multi-ligand mem-
brane receptor, and clusterin, that acts as an extracellular cha-
perone of amyloidogenic peptides but also exists within the cell,
both recently recognized for their role in amyloidogenesis were
assessed. Our results show that both were up-regulated in the two
backgrounds compared to wild type animals but tended to be
more overexpressed in the TM129/BL6 mice (Fig. 5A-B). Both
clusterin and megalin co-localize with TTR intracellularly (Fig. 5C).4. Discussion
In the present study we examined the effects of different ge-
netic backgrounds on amyloid deposition and various related
molecular pathogenic markers in a transgenic model of
ATTRV30M. Genetic background has previously been shown to
affect the phenotype and severity of other neurodegenerative
diseases, such as amyotrophic lateral sclerosis (ALS) [15–17].
Considering that the two lines of mice used in the current study
bear the same mutation with regards to the disease-causing locus,
our results suggest that genetic modiﬁers affect disease progres-
sion, or in this case, amyloid deposition.
The two lines of mice used here were the TM 129 mice, which
were on a pure 129 1/SvJ background and the TM129/BL6 mice
were on a mixture of 1291/SvJ and C57BL/6J backgrounds. The
Fig. 3. Western blot (A-E) comparisons of BiP in liver (A), Ubiquitin in liver (B) BiP in stomach (C) and Ubiquitin in stomach (D) in the two backgrounds.
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reference group, bearing in mind the number of generations used
for interbreeding. We have conﬁrmed, through real-time PCR, that
all mice used in this study carried the same number of disease
causing mutated human TTR transgenes (V30M) (Fig. 1A). Fur-
thermore, employing reverse transcription real-time PCR, we were
able to quantify the expression of hTTR in the liver, the main site of
TTR production (Fig. 1B). Our results indicate that TTR production
in liver cells was indeed equivalent in both lines of animals
(Fig. 2C). Secretion efﬁciency is likely similar in both lines since the
TTR mutation is the same and hepatic levels of BiP are also the
same (Fig. 3A). Therefore, any differences in amyloid deposition in
stomach are likely due to differences in recipient tissue handlingFig. 4. (A-C) Morphometric comparison of immunoﬂuorescence for Caspase-3, Fas and Cof the amyloidogenic protein.
Thioﬂavin S and TTR immunoﬂuorescence were used to provide
quantiﬁcation of the TTR speciﬁc amyloid deposits (Fig. 2A, B). Our
results indicate that as amyloid deposition progresses, the mixed
background mice appear to have less amyloid in the stomach (the
main site of deposition in this mouse model) than their 129 back-
ground counterparts. Blood and stomach non-ﬁbrillar TTR are simi-
larly lower in the mixed background mice. The lower levels of serum
and tissue non-ﬁbrillar TTR found in the mixed background animals
may be a result of enhanced peripheral tissue “clearance” (Fig. 2D, E).
“Clearance” refers to the amount of non-ﬁbrillar TTR that is
removed either from the circulation and/or from the extracellular
space and is either sequestered intracellularly and degraded in the5b9 in the two backgrounds along with representative images for Group C animals.
Fig. 5. (A) Morphometric comparison for megalin and Western blot comparison for clusterin (B) in the two backgrounds, (C) Intracellular co-localization of TTR with
clusterin (Ai-Aiv) and megalin (Av-Aviii) in stroma stomach cells.
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man and animal studies indicate that low levels of serum TTR have
been associated with more unstable and more amyloidogenic TTR
variants [18]. Furthermore human ATTRV30M carriers have a
lower level of TTR compared to non-carriers; while symptomatic
carriers have lower levels than asymptomatic carriers, presumably
as a result of mutated TTR penetrating and forming amyloid in
tissues in increasing amounts [19]. Interestingly a study of serum
TTR in a group of normal human controls showed that TTR con-
centration was statistically related to age, gender and ethnicity
[20]. The explanation is currently poorly understood but could
relate to genetic/age related variability in peripheral tissue
“clearance”.
In the stomach BiP appears signiﬁcantly higher in the TM 129
mice which also exhibited higher amyloid deposition. BiP has pre-
viously been associated with extracellular TTR plaques in tissue ob-
tained from FAP patients and been reported as an important bio-
marker that can be used to assess progression of the disease [21].
Ubiquitin on the other hand was expressed at higher levels in
the stomach of TM 129/BL6 mice at all ages despite lower levels of
extracellular TTR monomers and amyloid deposits (Fig. 3D).
Whether this relates to a higher internalization of TTR and ubi-
quitination by the resident cells is unclear however, it should be
noted that intracellular TTR have been reported in FAP murine
models. Intracellular localization of TTR has been previously de-
monstrated intracellularly in ﬁbroblasts, macrophages and
Schwann cells. Endocytosis of extracellular TTR as well as in-situ
synthesis are two possible explanations that been proposed
[22,23]. Another possibility may be that the higher ubiquitin levels
may be accounted for by the higher expression of clusterin which
is a highly poly-ubiquitinated protein in the TM 129/BL6 mice [20].
Higher ubiquitin levels also expressed in the liver of TM 129/BL6
mice perhaps suggesting that the two backgrounds have differentcapacities “to chaperoning at a distance “(Fig. 3B) [21].
Clusterin and megalin, tend to be more overexpressed in the
TM129/BL6 than the TM129 mice. Clusterin, an extracellular chaper-
one is overexpressed in both TTR amyloidotic neuropathy and TTR
amyloidotic cardiomyopathy and is thought to play a protective role
in TTR amyloidosis [5,6,24]. Megalin, a multi-ligand membrane re-
ceptor, binds clusterin and has been shown to mediate internaliza-
tion of TTR [7] (Fig. 5C). Thus, we hypothesize that the over-
expression of these two molecules results in higher rates of se-
questration and degradation of TTR in TM129/BL6 mice resulting in
less amyloid formation. A generic modulating role for clusterin and
megalin in the extracellular amyloidosis probably operates in the
light of data pertaining to Alzheimer disease [8,9,25].
In keeping with previously published work, outlining the
toxicity of both nonﬁbrillar TTR as well as ﬁbrillar TTR, molecular
markers of apoptosis (Fas and Caspase-3) and complement acti-
vation (C5b-9) were found to be signiﬁcantly up-regulated in both
backgrounds [21,26–28]. As expected these markers were more
up-regulated in the TM129 background animals which exhibited
greater amounts of non-ﬁbrillar and ﬁbrillar TTR (Fig. 4).
All currently available therapies for ATTRV30M amyloidosis aim
to drastically reduce blood TTR (liver transplantation, silencing
RNAs) or reduce the dissociation of TTR tetramers (Tafamidis, Di-
ﬂunisal) [29]. Other therapeutic approaches that perhaps should
be intensely considered are those that target molecular players
involved in modulation of amyloid deposition [25].Acknowledgments
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